Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Vasoactive intestinal peptide receptor

Introduction

There are two known receptors for the vasoactive intestinal peptide (VIP) termed VPAC1 and VPAC2.[1][2] These receptors bind both VIP and pituitary adenylate cyclase-activating polypeptide (PACAP) to some degree. Both receptors are members of the 7 transmembrane G protein-coupled receptor family.

VPAC1 is distributed widely in the CNS, liver, lung, intestine and T-lymphocytes.

VPAC2 is found in the CNS, pancreas, skeletal muscle, heart, kidney, adipose tissue, testis, and stomach.

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors are activated by the endogenous peptides VIP, PACAP-38, PACAP-27, peptide histidine isoleucineamide (PHI), peptide histidine methionineamide (PHM) and peptide histidine valine (PHV). β€œPACAP type II receptors” (VPAC1 and VPAC2 receptors) display comparable affinity for PACAP and VIP, whereas PACAP-27 and PACAP-38 are >100 fold more potent than VIP as agonists of most isoforms of the PAC1 receptor.[3]

References

References

  1. ↑ Laburthe M, Couvineau A, Marie JC (2002). “VPAC receptors for VIP and PACAP”. Recept. Channels. 8 (3–4): 137–53. doi:10.1080/10606820213680. PMIDΒ 12529932.
  2. ↑ Laburthe M, Couvineau A (2002). “Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP”. Regul. Pept. 108 (2–3): 165–73. doi:10.1016/S0167-0115(02)00099-X. PMIDΒ 12220741.
  3. ↑ “VIP and PACAP receptors”. IUPHAR Guide to Pharmacology. The British Pharmacological Society (BPS) and the International Union of Basic and Clinical Pharmacology (IUPHAR).
External links